Atara biotherapeutics to present eight abstracts at the 63rd american society of hematology (ash) annual meeting, including first presentation of tab-cel® pivotal phase 3 (allele) data

South san francisco, calif.--(business wire)--atara biotherapeutics, inc. (nasdaq: atra), a leader in t-cell immunotherapy, leveraging its novel allogeneic epstein-barr virus (ebv) t-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the upcoming first release of efficacy and safety results from its phase 3 allele study. the pivotal trial is investigating tabelecleucel (tab-cel®) for the treatment of epstein-barr virus-positive po
ATRA Ratings Summary
ATRA Quant Ranking